Vaxcyte (NASDAQ:PCVX) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Vaxcyte (NASDAQ:PCVX) released its quarterly earnings data on Wednesday. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.09, FiscalAI reports. During the same period last year, the company posted ($1.22) earnings per share.

Vaxcyte Stock Performance

Shares of PCVX traded up $1.23 during trading hours on Wednesday, hitting $55.92. 886,273 shares of the company were exchanged, compared to its average volume of 972,456. The company has a market cap of $8.07 billion, a PE ratio of -8.13 and a beta of 1.23. The firm’s 50 day moving average is $53.56 and its 200-day moving average is $55.10. Vaxcyte has a 52 week low of $29.08 and a 52 week high of $65.00.

More Vaxcyte News

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Quarterly loss was narrower than expected: Vaxcyte reported second-quarter EPS of negative $1.97, beating the consensus estimate of negative $2.06. Although the loss widened from negative $1.22 a year earlier, the earnings beat likely helped sentiment. Vaxcyte quarterly earnings release
• Positive Sentiment: Important VAX-31 trial updates are approaching: Topline safety, tolerability and immunogenicity data from the adult Phase 3 OPUS-1 trial are expected in the fourth quarter of 2026. Results from the OPUS-2 and OPUS-3 trials are expected in the first half of 2027, giving investors several potential catalysts. Vaxcyte second-quarter 2026 business update
• Positive Sentiment: Strong liquidity reduces near-term financing risk: Vaxcyte had approximately $2.5 billion in cash, cash equivalents and investments as of June 30, 2026, providing substantial funding for its late-stage vaccine programs and development of VAX-A1.
• Neutral Sentiment: Analyst consensus remains cautious: Brokerages recently assigned Vaxcyte a consensus “Hold” rating, suggesting that valuation, clinical execution and the company’s ongoing losses remain areas of investor concern. Vaxcyte consensus rating report
• Negative Sentiment: Several executives sold shares: The CFO, COO and another insider sold a combined 29,250 shares for approximately $1.6 million. Each transaction was conducted under a pre-arranged Rule 10b5-1 plan, which reduces the significance of the sales but may still weigh modestly on sentiment.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on PCVX shares. Zacks Research cut shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Wall Street Zen lowered shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Vaxcyte has an average rating of “Hold” and an average target price of $86.00.

Insider Buying and Selling

In related news, insider Harpreet S. Dhaliwal sold 17,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $55.00, for a total value of $935,000.00. Following the transaction, the insider directly owned 76,756 shares of the company’s stock, valued at approximately $4,221,580. This trade represents a 18.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $57.28, for a total value of $572,800.00. Following the completion of the sale, the chief financial officer owned 104,395 shares of the company’s stock, valued at approximately $5,979,745.60. This trade represents a 8.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 120,646 shares of company stock worth $6,570,810. Insiders own 3.30% of the company’s stock.

Institutional Trading of Vaxcyte

Institutional investors and hedge funds have recently modified their holdings of the company. Alberta Investment Management Corp acquired a new position in Vaxcyte in the 4th quarter valued at $1,389,000. Vident Advisory LLC raised its holdings in Vaxcyte by 12.9% in the 4th quarter. Vident Advisory LLC now owns 8,821 shares of the company’s stock worth $407,000 after acquiring an additional 1,007 shares during the period. ADAR1 Capital Management LLC lifted its position in Vaxcyte by 48.1% during the 4th quarter. ADAR1 Capital Management LLC now owns 315,642 shares of the company’s stock worth $14,564,000 after acquiring an additional 102,578 shares during the last quarter. Empowered Funds LLC acquired a new position in Vaxcyte during the 4th quarter worth $211,000. Finally, XTX Topco Ltd bought a new stake in Vaxcyte during the fourth quarter valued at about $704,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.